Community-acquired pneumonia: what's new in management?

Internal Medicine · Pulmonology · Infectious Disease · General Medicine

Community-acquired pneumonia (CAP) is a common lower respiratory tract infection acquired outside hospital settings and remains an important cause of morbidity, hospitalisation and mortality worldwide. Its clinical presentation ranges from mild respiratory illness requiring outpatient treatment to severe pneumonia associated with respiratory failure, sepsis and septic shock. Streptococcus pneumoniae remains an important bacterial pathogen, although atypical bacteria and respiratory viruses also contribute to the disease burden. Management is guided by disease severity, underlying comorbidities, likely causative organisms and local antimicrobial resistance patterns. Recent approaches have emphasised timely antibiotic administration, appropriate antimicrobial selection, individualised treatment duration and early transition from intravenous to oral therapy.[1]Antibiotic therapy: Early initiation and appropriate selectionEarly initiation of antibiotic therapy is particularly important in severe CAP. Antibiotic administration within approximately four hours of diagnosis has been associated with reduced mortality in patients with severe disease. Treatment selection should be guided by clinical severity, suspected aetiology, previous antibiotic exposure, comorbidities and regional antimicrobial resistance patterns.Outpatient management: Patients with mild CAP may be managed at home when adherence to the prescribed antibiotic regimen and appropriate clinical follow-up can be ensured. In otherwise healthy individuals without significant comorbidities or risk factors for antimicrobial resistance, beta-lactam or macrolide monotherapy may be consideredThe need for routine coverage against atypical pathogens in mild CAP remains debated, as additional benefits have not been consistently demonstrated. Recommendations also differ across international guidelines because of variations in pneumococcal and macrolide resistanceOutpatient monotherapy with a beta-lactam or macrolide has been recommended for patients without comorbidities, recent antibiotic exposure or risk factors for resistance. Azithromycin may be preferred over Clarithromycin in patients with COPD because of its greater in-vitro activity against most Haemophilus influenzae strains. Fluoroquinolones are generally avoided in otherwise healthy outpatients because of concerns regarding potentially serious adverse effectsFor patients with comorbidities, including COPD, diabetes, chronic kidney or liver disease, malignancy, congestive heart failure, alcoholism or immunosuppression, broader antimicrobial coverage is required. Similar considerations apply to individuals who have received antibiotics within the preceding three months or reside in regions with high macrolide resistancePatient categoryRecommended antibiotic approachOtherwise healthy outpatientsBeta-lactam or macrolide monotherapy, depending on local resistance patterns.Patients with comorbidities or recent antibiotic exposureBeta-lactam plus macrolide or respiratory fluoroquinolone monotherapy.Suspected Gram-negative infectionAmoxicillin-Clavulanate may be considered, although atypical pathogens are not covered.A minimum treatment duration of five days is generally recommended for uncomplicated cases with an adequate clinical response.Inpatient management: General wardFor hospitalised patients with non-severe CAP, two principal antibiotic strategies are recommended: Respiratory fluoroquinolone monotherapy or combination therapy comprising a beta-lactam and a macrolide. Macrolide monotherapy is generally contraindicated because of the high prevalence of S. pneumoniae resistance. Beta-lactam monotherapy should be considered only when Legionella infection has been excluded. Although the requirement for atypical pathogen coverage remains debated, combination therapy is frequently preferred to provide broader antimicrobial coverage.Potential treatment options include:Respiratory fluoroquinolones: Levofloxacin, Moxifloxacin or GemifloxacinBeta-lactams combined with macrolides: Ceftriaxone or Cefuroxime with Azithromycin or ClarithromycinIntensive care management: Severe CAPSevere CAP, particularly when accompanied by septic shock, requires prompt antimicrobial treatment and supportive care. Combination antibiotic therapy is generally preferred over monotherapy in these patientsBeta-lactam plus macrolide therapy has demonstrated better outcomes than beta-lactam plus fluoroquinolone combinations in some systematic reviews and meta-analyses. Potential explanations include improved coverage of atypical pathogens, immunomodulatory effects of macrolides and pharmacological synergy. However, further randomised trials are neededAntibiotic selection should also account for the possibility of Pseudomonas aeruginosa infection.Important risk factors for Pseudomonas infection include:Structural lung disease, including bronchiectasis, cystic fibrosis or severe COPD (FEV1 below 30%)Neutropenia (below 1,000/mm3)Chronic corticosteroid use exceeding 10 mg/day of Prednisone or equivalentAntibiotic exposure exceeding seven days within the preceding 30 daysHospitalisation within the preceding seven daysIn patients without these risk factors, Ceftriaxone or Cefuroxime combined with a macrolide, or a beta-lactam combined with Levofloxacin or Moxifloxacin, may be considered. When Pseudomonas risk is identified, broader antimicrobial agents, including Piperacillin-Tazobactam, Meropenem, respiratory fluoroquinolones and, in selected circumstances, Polymyxin B, may be incorporated into treatment.Treatment duration and therapeutic monitoringThe optimal duration of antibiotic therapy depends on disease severity, causative pathogen, complications and clinical response. Treatment discontinuation should be guided by clinical stability, including absence of fever for 48-72 hours and overall symptomatic improvement. Declining leukocyte counts, C-reactive protein and procalcitonin may provide additional informationFor patients demonstrating a favourable clinical response, antibiotic treatment may generally be completed within approximately five to seven days. Longer courses may be required in complicated infections or when specific pathogens necessitate extended treatmentIn suspected influenza A (H1N1)-associated pneumonia, antiviral treatment should be administered alongside appropriate antibacterial coverage when pneumococcal or Staphylococcus aureus coinfection is suspectedAdjunctive treatment and hospital dischargeSystemic corticosteroids have gained attention as adjunctive therapy in severe CAP. Their administration has been associated with shorter hospital stays, reduced treatment failure, less radiological progression and decreased requirements for mechanical ventilation. Nevertheless, uncertainties regarding their effects on mortality, optimal dosing and treatment duration remain, warranting further investigationOnce clinical improvement has been achieved and patients are haemodynamically stable, intravenous antibiotics may be converted to oral formulations. Continuation of the same agent or an antibiotic from the same class is generally preferred to facilitate early discharge and reduce treatment costsHospital discharge should be considered when clinical improvement has been demonstrated and the patient is sufficiently stable to continue treatment outside the hospitalConclusionThe management of CAP requires an individualised approach based on disease severity, comorbidities, suspected pathogens and local antimicrobial resistance. Early antibiotic administration, appropriate selection of empirical regimens and timely adjustment of treatment remain central to improving outcomes. Combination therapy is particularly important in severe CAP, while treatment duration should be guided by clinical stability rather than fixed schedules alone. Appropriate use of adjunctive corticosteroids, early intravenous-to-oral antibiotic conversion and clinically guided discharge further contribute to optimising patient management and reducing healthcare-associated costs.[2]Reference(s):1. Dequin PF, Torres A, Bassetti M, et al. Severe community-acquired pneumonia: current concepts and controversies. Intensive Care Med. 2026;52(1):118-130. doi:10.1007/s00134-025-08252-x. https://pmc.ncbi.nlm.nih.gov/articles/PMC12852277/2. Keynan Y, Lother SA, Laupland K, et al. Diagnosing and Treating Community-Acquired Pneumonia-A Double-Blind Study?. J Assoc Med Microbiol Infect Dis Can. 2025;10(2):97-100. Published 2025 Jun 27. doi:10.3138/jammi-2025-0226. https://pmc.ncbi.nlm.nih.gov/articles/PMC12253938/